GTx, Inc. Share Price Nasdaq
Equities
US40052B1089
Biotechnology & Medical Research
Sales 2024 * | 538K 44.84M | Sales 2025 * | 675K 56.31M | Capitalization | 24.42M 2.04B |
---|---|---|---|---|---|
Net income 2024 * | -37M -3.09B | Net income 2025 * | -48M -4B | EV / Sales 2024 * | 45.4 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 36.2 x |
P/E ratio 2024 * |
-0.77
x | P/E ratio 2025 * |
-0.98
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.77% |
Latest transcript on GTx, Inc.
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 01/97/01 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 01/17/01 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 17/21/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 01/97/01 |
Dan Kisner
BRD | Director/Board Member | 77 | 07/19/07 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 27/21/27 |
1st Jan change | Capi. | |
---|---|---|
+24.79% | 42.68B | |
-3.27% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.58% | 24.94B | |
-20.02% | 18.96B | |
+29.25% | 12.3B | |
-2.77% | 11.95B | |
-1.48% | 11.55B |